HK1232235A1 - 治療和診斷過表達α- -β- 的癌症的方法 - Google Patents

治療和診斷過表達α- -β- 的癌症的方法

Info

Publication number
HK1232235A1
HK1232235A1 HK17105807.3A HK17105807A HK1232235A1 HK 1232235 A1 HK1232235 A1 HK 1232235A1 HK 17105807 A HK17105807 A HK 17105807A HK 1232235 A1 HK1232235 A1 HK 1232235A1
Authority
HK
Hong Kong
Prior art keywords
beta
treating
methods
overexpressing cancer
diagnosing alpha
Prior art date
Application number
HK17105807.3A
Other languages
English (en)
Inventor
Simon T Barry
John F Marshall
Kate M Moore
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Publication of HK1232235A1 publication Critical patent/HK1232235A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
HK17105807.3A 2013-10-01 2017-06-13 治療和診斷過表達α- -β- 的癌症的方法 HK1232235A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361885302P 2013-10-01 2013-10-01
PCT/EP2014/071028 WO2015049280A1 (en) 2013-10-01 2014-10-01 Methods of treating and diagnosing alpha-v-beta-6 overexpressing cancer

Publications (1)

Publication Number Publication Date
HK1232235A1 true HK1232235A1 (zh) 2018-01-05

Family

ID=51655742

Family Applications (1)

Application Number Title Priority Date Filing Date
HK17105807.3A HK1232235A1 (zh) 2013-10-01 2017-06-13 治療和診斷過表達α- -β- 的癌症的方法

Country Status (8)

Country Link
US (2) US20160319032A1 (zh)
EP (1) EP3052523B1 (zh)
JP (2) JP6527508B2 (zh)
CN (1) CN106232625B (zh)
AU (1) AU2014331118B2 (zh)
CA (1) CA2925057A1 (zh)
HK (1) HK1232235A1 (zh)
WO (1) WO2015049280A1 (zh)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10441654B2 (en) 2014-01-24 2019-10-15 Children's Hospital Of Eastern Ontario Research Institute Inc. SMC combination therapy for the treatment of cancer
RU2768186C2 (ru) * 2015-12-11 2022-03-23 Рупрехт-Карлс-Университет Гейдельберг Комбинированные лекарственные средства, содержащие модуляторы pkm2 и hmgb1
AU2017269335B2 (en) 2016-05-26 2021-07-01 Recurium Ip Holdings, Llc EGFR inhibitor compounds
JP7022081B2 (ja) * 2016-06-14 2022-02-17 メルク・シャープ・アンド・ドーム・コーポレーション 抗凝固因子ｘｉ抗体
AU2018209164B2 (en) 2017-01-17 2021-11-04 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
CN106950371B (zh) * 2017-02-17 2019-03-08 张灏 Pd-l1、cdk5和ctla4中的至少一种在制备肿瘤诊断试剂盒中的用途
KR102630070B1 (ko) * 2017-03-31 2024-01-26 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 알파-v 베타-3-양성인 암 줄기 세포(csc)를 표적화하여 사멸시키고 약물 내성 암을 치료하기 위한 조성물 및 방법
CN109265551B (zh) * 2018-09-25 2020-09-15 华东师范大学 Cd38抗体、嵌合抗原受体和药物
CA3143952A1 (en) * 2019-02-22 2020-08-27 Candel Therapeutics, Inc. Gmci and ddri combination therapy for treating cancer
AU2020397070A1 (en) 2019-12-05 2022-07-14 Seagen Inc. Anti-avb6 antibodies and antibody-drug conjugates
CN114195893A (zh) * 2020-09-17 2022-03-18 百奥泰生物制药股份有限公司 抗整联蛋白抗体或抗原结合片段及其应用
CN117603348B (zh) * 2023-11-24 2024-08-09 优睿赛思(武汉)生物科技有限公司 抗新型冠状病毒s蛋白的全人源化抗体及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ535425A (en) * 2002-03-13 2008-05-30 Biogen Idec Inc Anti-alphavbeta6 antibodies
CN104072614B (zh) * 2005-07-08 2017-04-26 生物基因Ma公司 抗-αvβ6 抗体及其用途
MX2009001293A (es) * 2006-08-03 2009-02-11 Astrazeneca Ab Anticuerpos dirigidos a (v(6 y usos de los mismos.
JP6273214B2 (ja) * 2012-02-17 2018-01-31 シアトル ジェネティックス， インコーポレイテッド がんを処置するためのインテグリンαｖβ６に対する抗体およびその使用

Also Published As

Publication number Publication date
JP2016539083A (ja) 2016-12-15
US20190389967A1 (en) 2019-12-26
JP2019142876A (ja) 2019-08-29
CA2925057A1 (en) 2015-04-09
JP6527508B2 (ja) 2019-06-05
EP3052523A1 (en) 2016-08-10
US20160319032A1 (en) 2016-11-03
CN106232625A (zh) 2016-12-14
AU2014331118B2 (en) 2019-07-25
AU2014331118A1 (en) 2016-05-19
WO2015049280A1 (en) 2015-04-09
CN106232625B (zh) 2020-04-24
EP3052523B1 (en) 2021-03-10

Similar Documents

Publication Publication Date Title
HK1232235A1 (zh) 治療和診斷過表達α- -β- 的癌症的方法
HK1218506A1 (zh) 治療黑素瘤的方法
IL244709A0 (en) Methods for diagnosis and treatment of eosinophilic disorders
HK1217908A1 (zh) 治療膽管癌的方法
HK1220473A1 (zh) 抗-α-突觸核蛋白抗體及使用方法
HK1258446A1 (zh) 診斷和治療焦慮症的方法
EP2970317A4 (en) PYRIMIDODIAZEPINONE COMPOUNDS AND METHOD FOR THE TREATMENT OF DISEASES
PL3046470T3 (pl) Diagnozowanie i leczenie zaburzeń ruchu
ZA201506534B (en) Method of treating hair
HK1224307A1 (zh) 原毒素- 變體及其使用方法
EP2929831A4 (en) ENDOSCOPE SYSTEM AND METHOD OF OPERATING THE ENDOSCOPE SYSTEM
PL3071969T3 (pl) Sposób analizy
IL276431A (en) Treatment of the brain disorders and related symptoms
EP2968366A4 (en) METHODS OF TREATING TESTOSTERONE DEFICIENCY
HK1220453A1 (zh) 治療運動障礙和相關病症的方法
HK1212999A1 (zh) 用於治療和/或限制糖尿病的發展的方法
IL241096A0 (en) Treatment methods
IL239909A0 (en) Methods for treating cardiovascular signs
HK1183708A1 (zh) 種檢測牡丹皮的方法
HK1222389A1 (zh) 肺病症和其他病症的治療
IL246185A0 (en) Methods and compositions for treating dysregulation in systems
EP2971066A4 (en) PROCESS FOR IDENTIFICATION AND USE OF NEMATIC COMPOUNDS
ZA201406383B (en) Method of taking fingerprints
GB201322778D0 (en) Method of treatment
GB201314882D0 (en) Method of treatment